-
-
The Cost of Attacking the Pharmaceutical Industry
Trump
Trump's policies during his second term have rocked the U.S. scientific community, slashing NIH funding, threatening pharmaceutical innovation, and reshaping the global research landscape amid rising concerns about America's future in science.
-
NIH Cuts and the Future of U.S. Biopharma
NIH
Trump's proposed NIH budget cuts, agency consolidations, and funding restrictions could reshape U.S. biomedical research, strain U.S.-China collaborations, and shift national priorities toward AI and space tech.
-
Trump's Presidency: Impact on the U.S. Biopharma Industry
FDA
Explore the implications of Trump's return on U.S. biopharma: healthcare cost reforms, IRA adjustments, reshoring manufacturing, and FDA/NIH shifts. Key focus areas for Chinese pharma include supply chain resilience and navigating new cross-border data regulations.
-
-
Tecovirimat Ineffective for Clade I Mpox in DRC Study
NIH
A recent NIH study in the Democratic Republic of the Congo found that tecovirimat does not improve clade I mpox lesion resolution. Despite this, mortality rates were lower than average. The study emphasizes the need for more research on effective treatments and vaccines for clade I mpox.
-
-
-
-
承德市|
桦南县|
江都市|
东光县|
青龙|
临澧县|
孙吴县|
德昌县|
宿迁市|
都江堰市|
鄂伦春自治旗|
邛崃市|
万全县|
民县|
岳池县|
松桃|
嘉善县|
大竹县|
湟中县|
勃利县|
福鼎市|
南部县|
天水市|
侯马市|
黄浦区|
开封县|
珠海市|
简阳市|
富宁县|
舟曲县|
玉田县|
乌兰浩特市|
留坝县|
安康市|
日土县|
同德县|
中宁县|
吉隆县|
元阳县|
南部县|
平南县|